Chelsea Therapeutics: Caution Warranted

Chelsea Therapeutics: Caution Warranted

On February 18th 2014, Chelsea Therapeutics International, Ltd. (NASDAQ:CHTP) that the U.S. Food and Drug Administration (FDA) granted accelerated approval of NORTHERATM (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA represents the only therapy approved by the FDA, which demonstrates symptomatic benefit in patients with NOH. This autonomic disorder manifests with symptoms including dizziness, lightheadedness, blurred vision, fatigue, poor concentration and fainting episodes. The pathophysiology of NOH is caused by an endogenous insufficiency to produce and release sufficient levels of norepinephrine upon standing. The disorder affects an estimated 80,000 to 150,000 individuals in the United States. While this is a major accomplishment for Chelsea shareholders and patients with NOH, there remains...

Professional Idea Filters to zero-in based on industry, market cap and more

"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital

"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management

You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details